When AI meets Stem Cells: spotlight on our work with I-Stem
Kantify and I-Stem work together for faster rare disease drug discovery
Rare diseases affect a significant portion of the population, yet unfortunately, the vast majority of them still do not have a cure. However, despite these challenges, there is hope on the horizon. With a focused approach and strategic partnerships, we are determined to change the situation and make a difference in the lives of those affected by rare diseases.
In honor of Rare Disease Day 2023, we want to shine a spotlight on the groundbreaking collaboration between Kantify and the French Research Centre for Stem Cell Studies ( I-Stem/CECS). This partnership is dedicated to drug discovery for rare monogenic diseases, utilizing cutting-edge technology to advance the development of effective treatments.
By combining the power of Artificial Intelligence and Stem Cells, this collaboration is accelerating the discovery of therapeutic targets and drugs for patients affected by rare diseases. This innovative approach has the potential to transform the field of rare disease research, offering new hope and promising outcomes for those who are affected by these debilitating conditions.
At Kantify, we are committed to making a difference in the lives of those affected by rare diseases. Through partnerships like the one with I-Stem, we are working towards a brighter future where effective treatments for rare diseases are within reach. Join us in supporting this important mission, and together we can make a difference for those who need it most.